Compare MITT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITT | ACIU |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.5M | 247.6M |
| IPO Year | 2011 | 2015 |
| Metric | MITT | ACIU |
|---|---|---|
| Price | $5.46 | $2.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $8.58 | $8.57 |
| AVG Volume (30 Days) | ★ 413.7K | 201.4K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | ★ 18.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $422.39 |
| Revenue Next Year | $11.69 | $377.85 |
| P/E Ratio | $533.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.20 | $2.10 |
| 52 Week High | $9.27 | $4.00 |
| Indicator | MITT | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 45.80 |
| Support Level | N/A | $2.40 |
| Resistance Level | $8.00 | $2.68 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 33.56 | 34.18 |
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.